OCT 14, 2019 2:21 PM PDT

Injectable Drug reverses symptoms of liver disease in people with HIV

WRITTEN BY: Nouran Amin

In a study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute, scientists report that an injectable hormone ‘tesamorelin’ works to reduce liver fat and prevent liver fibrosis (scarring) in HIV patients with non-alcoholic fatty liver disease, or NAFLD.

National Institute of Allergy and Infectious Disease: A microscopic image of liver tissue affected by non-alcoholic fatty liver disease (NAFLD). The large and small white spots are excess fat droplets filling liver cells (hepatocytes). Credit: Dr. David Kleiner, NCI

"Many people living with HIV have overcome significant obstacles to live longer, healthier lives, though many still experience liver disease," said NIAID Director Anthony S. Fauci, M.D. "It is encouraging that tesamorelin, a drug already approved to treat other complications of HIV, may be effective in addressing non-alcoholic fatty liver disease."

Learn more about non-alcoholic fatty liver disease, or NAFLD:

 

 

"Our hope is that this intervention may help people living with HIV, as well as benefit HIV-negative people with liver abnormalities," said Dr. Hadigan. "Further research may inform us of the potential long-term benefits of this approach and develop formulations that can benefit everyone with liver disease, regardless of HIV status."

Tesamorelin, also known as Egrifta, was approved by the U.S. Food and Drug Administration in 2010 and works to reduce excess fat around the abdomen. Findings were published in The Lancet HIV.

"Because tesamorelin proved effective in treating abnormal fat build-up in the abdomens of people in the context of HIV and related medication use, we hypothesized that the drug might also reduce fat that accrues in the liver and causes damage in a similar population," said Steven K. Grinspoon, M.D., Chief of the Metabolism Unit at MGH.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 09, 2021
Cannabis Sciences
Top Benefits of Having Your Medical Marijuana Card
MAR 09, 2021
Top Benefits of Having Your Medical Marijuana Card
With the use of medicinal marijuana booming, estimated at almost 4.5 million patients in 2020, it’s time to talk a ...
MAR 12, 2021
Drug Discovery & Development
Drug Starves Melanoma Tumors
MAR 12, 2021
Drug Starves Melanoma Tumors
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a drug candidate that blocks the uptake ...
APR 14, 2021
Drug Discovery & Development
Anti-Aging Compound Improves Glucose Uptake
APR 14, 2021
Anti-Aging Compound Improves Glucose Uptake
According to new research at Washington University School of Medicine in St. Louis, a substance shown to counteract aspe ...
MAY 11, 2021
Genetics & Genomics
Gene Therapy Trial for Severe Immune Disorder is Successful
MAY 11, 2021
Gene Therapy Trial for Severe Immune Disorder is Successful
Severe combined immunodeficiency (SCID), which virtually eliminates a patient's immune system, and severely affects thei ...
JUN 03, 2021
Drug Discovery & Development
Smartphone App More Effective than Traditional Treatment for Osteoarthritis
JUN 03, 2021
Smartphone App More Effective than Traditional Treatment for Osteoarthritis
  Researchers at the University of Nottingham in the UK and Joint Academy have found that a clinical evidence-based ...
JUN 17, 2021
Drug Discovery & Development
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
JUN 17, 2021
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
The FDA recently approved a new drug known as Adulhelm, or aducanumab, to treat Alzheimer’s disease. The first new ...
Loading Comments...